摘要
目的探讨硫普罗宁联合奥沙利铂对肿瘤的临床疗效和用药安全性。方法通过对本院2006年1月至2011年9月病理证实肺癌患者60例使用奥沙利铂130 mg/m2,静脉滴注2 h,第1和第8天硫普罗宁0.2 g配5%的葡萄糖注射液250 ml,静脉滴注,1次/d。治疗前后给予止吐药,21～28 d为一个周期,2个周期后对患者病情进行一次评估。结果 60例患者其中CR 6例(10%),PR 23例(38.33%),SD 25例(41.67%),PD 6例(10%),总有效率48.33%;该药物组合的主要毒副作用是骨髓抑制和胃肠道反应。结论硫普罗宁联合奥沙利铂对肺癌疗效好,副作用小,临床上值得推广。
Objective To investigate the clinical efficacy and drug safety tiopronin combined with oxaliplatin in the tumor. Methods The hospital in January 2006 to 2011 September pathologically confirmed 60 cases of lung cancer patients with oxaliplatin 130 mg/m2, intravenous infusion for 2 h, 1 and 8 days tiopronin 0. 2 g with 5% Glucose Injection 250 ml intravenous infusion once a day. Antiemetic drugs before and after treatment,21 - 28 d for a period of two cycles to undertake an assessment of the patient＇s condition. Results 60 patients in which the CR 6 patients （ 10% ）, PR 23 cases （38.33%） , the SD 25 cases （41.67%） the PD 6 cases （10%）, the total efficiency of 48.33%, the main side effects of the combination of drugs was bone marrow suppression and gastrointestinal reactions. Conclusion The tiopronin United oxaliplatin on lung cancer, side effects in clinical practice is worth promoting.
出处
《中国实用医药》
2012年第10期51-52,共2页
China Practical Medicine
